Literature DB >> 21544318

Are P2Y12 reaction unit (PRU) and % inhibition index equivalent for the expression of P2Y12 inhibition by the VerifyNow assay? Role of haematocrit and haemoglobin levels.

Sophie Voisin1, Vanina Bongard, Mohammed A Tidjane, Thibault Lhermusier, Didier Carrié, Pierre Sié.   

Abstract

The results of the whole blood VerifyNow P2Y12 assay can be expressed as platelet reaction units (PRU) or % inhibition index (%inh), but an optimal cut-off for the assessment of high on-treatment platelet reactivity (HPR) predictive of clinical events has been validated only for PRU. The aim of the study was to study the influence of haematological variables, such as platelet and leukocyte counts or haematocrit / haemoglobin, within the limits indicated by the manufacturer for assay validity, on the results of the test. We performed a comparison of PRU and %inh in a series 186 samples obtained from a clinical trial on patients under dual antiplatelet therapy. The results show that PRU significantly decreases with increasing haematocrit / haemoglobin, whereas %inh does not, due to a parallel change in PRU and iso-TRAP baseline value. PRU and % inhibition index are not equivalent for the definition of HPR, because of their different sensitivities to haematocrit / haemoglobin.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21544318     DOI: 10.1160/TH11-01-0046

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

1.  A high ratio of ADP-TRAP induced platelet aggregation is associated more strongly with increased mortality after coronary stent implantation than high conventional ADP induced aggregation alone.

Authors:  Christoph B Olivier; Katharina Schnabel; Christoph Brandt; Patrick Weik; Manfred Olschewski; Qian Zhou; Christoph Bode; Philipp Diehl; Martin Moser
Journal:  Clin Res Cardiol       Date:  2014-07-16       Impact factor: 5.460

2.  Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease.

Authors:  Haiyan Li; Jingchuan Guo; Glenn F Carlson; Renli Teng
Journal:  Br J Clin Pharmacol       Date:  2016-06-09       Impact factor: 4.335

Review 3.  Clinical pharmacokinetics and pharmacodynamics of clopidogrel.

Authors:  Xi-Ling Jiang; Snehal Samant; Lawrence J Lesko; Stephan Schmidt
Journal:  Clin Pharmacokinet       Date:  2015-02       Impact factor: 6.447

4.  Different influences of hematocrit on the results of two Point-Of-Care platelet function tests, the VerifyNow assay and multiple electrode platelet aggregometry.

Authors:  Yun Gi Kim; Jung-Won Suh; Jin Joo Park; Il-Young Oh; Chang-Hwan Yoon; Young-Seok Cho; Tae-Jin Youn; In-Ho Chae; Dong-Ju Choi
Journal:  PLoS One       Date:  2014-11-26       Impact factor: 3.240

5.  Predictors of high on-aspirin platelet reactivity in elderly patients with coronary artery disease.

Authors:  J W Zhang; W W Liu; Timothy A McCaffrey; X Q He; W Y Liang; X H Chen; X R Feng; Sidney W Fu; M L Liu
Journal:  Clin Interv Aging       Date:  2017-08-10       Impact factor: 4.458

6.  A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity.

Authors:  Joseph A Jakubowski; Chunmei Zhou; David S Small; Kenneth J Winters; D Richard Lachno; Andrew L Frelinger; Jo Howard; Timothy G Mant; Stipo Jurcevic; Christopher D Payne
Journal:  Br J Clin Pharmacol       Date:  2013-06       Impact factor: 4.335

7.  The Ratio of ADP- to TRAP-Induced Platelet Aggregation Quantifies P2Y12-Dependent Platelet Inhibition Independently of the Platelet Count.

Authors:  Christoph B Olivier; Melanie Meyer; Hans Bauer; Katharina Schnabel; Patrick Weik; Qian Zhou; Christoph Bode; Martin Moser; Philipp Diehl
Journal:  PLoS One       Date:  2016-02-17       Impact factor: 3.240

8.  Platelet activity with hemoglobin level in patients with hemodialysis: Prospective study.

Authors:  Jae Min Kim; Jin Sug Kim; Hyung Oh Kim; So Ra Lee; Jae Hwan Rhew; Jong Shin Woo; Jang Hyun Cho; Kyung Hwan Jeong; Weon Kim
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.